Site icon OncologyTube

Second-Line VEGFR TKI Outcomes After First-Line Immune Checkpoint Blockade in Metastatic Renal Cell Carcinoma

Ritesh Kotecha discusses Second-Line VEGFR TKI Outcomes After First-Line Immune Checkpoint Blockade in Metastatic Renal Cell Carcinoma at the Seventeenth International Kidney Cancer International Symposium 2018 in Miami FL.

Exit mobile version